Why Is RVTY Stock Surging in Premarket? Q4 Revenue Outlook Tops Expectations

Revvity, Inc. (NYSE:RVTY) shares jumped significantly in premarket trading on January 13, 2026, following the company’s announcement that it expects to exceed its fourth quarter 2025 guidance. The medical equipment and life sciences company disclosed preliminary results showing Q4 revenue of approximately $772 million, representing 6% reported growth and 4% organic growth year-over-year. The stock was trading at $112.30 in premarket, up $8.37 or 8.05% from the previous close of $103.89 as of 6:03 AM EST.

Revenue Outlook Surpasses Estimates

The Waltham, Massachusetts-based company announced Monday that its fourth quarter revenue outlook of approximately $772 million exceeded Wall Street estimates of $760.3 million. The 6% reported growth and 4% organic growth compared to the same period in 2024 demonstrates renewed momentum in the life sciences and diagnostics sector.

This performance continues Revvity’s trend of steady expansion, with the company having posted 3.37% growth over the last twelve months.

For the full year 2025, Revvity projects revenue of approximately $2.855 billion, reflecting 4% reported growth and 3% organic growth year-over-year. This full-year figure also surpassed analyst estimates of $2.84 billion, reinforcing investor confidence.

The company’s preliminary results indicate strong demand for contract research and diagnostics services across its pharmaceutical, biotech, diagnostic labs, academia, and government customer base spanning more than 160 countries.

Join our Telegram group and never miss a breaking digital asset story.

Full-Year Earnings Outlook Raised

In addition to the revenue beat, Revvity indicated that its full-year adjusted earnings per share will exceed the upper end of its previous guidance range of $4.90-$5.00, which was provided on October 27, 2025. While analysts had forecast fiscal year 2025 EPS at $5.06, the company’s updated outlook suggests it will surpass even these projections.

This marks a significant achievement for the diagnostics and research company, which currently trades with a P/E ratio of 53.04 and maintains a market capitalization of $11.8 billion.

The company plans to release complete fourth quarter and full year 2025 financial results before market open on Monday, February 2, 2026, followed by a conference call at 8:00 a.m. ET. President and CEO Prahlad Singh is also scheduled to present at the 44th annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT.

With approximately 11,000 employees and a 56-year track record of consecutive dividend payments, Revvity continues to position itself as a stable player in the health sciences solutions market.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.